-
2025-521284-12-00
5
2026-03-05
Non-small cell lung cancer
-
2025-521785-10-00
5
2026-03-04
Glioblastoma
-
2025-522015-42-00
10
2026-02-26
Chronic Hepatitis D Infection
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2024-519404-27-00
5
2026-01-16
IDH-mutant grade 2 or 3 astrocytoma
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2025-522860-34-00
5
2025-12-16
Small lymphocytic lymphoma (SLL)
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2025-520896-13-00
5
2025-12-04
Friedreich’s ataxia
-
2025-521242-26-00
4
2025-11-27
Moderately to Severely Active Ulcerative Colitis
-
2025-521744-37-00
5
2025-11-17
Mild to moderate major depressive disorder
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-517553-26-00
5
2025-11-12
Advanced ALK-positive non-small cell lung cancer (NSCLC)
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2025-521564-35-00
4
2025-11-06
ischemic stroke with intracranial large artery occlusion of the anteri
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-516924-32-00
5
2025-10-17
Neovascular Age-Related Macular Degeneration (nAMD)
-
2025-520490-38-00
3
2025-10-13
Haemophilia A with or without inhibitors. Proposed indication under de
-
2024-515682-34-00
5
2025-10-06
Chronic migraine
-
2024-515715-22-00
5
2025-10-06
Episodic migraine
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P